Group 1 - The stock price of XinTai Medical (02291.HK) closed at HKD 23.550 on April 22, representing a 47.19% increase from the previous trading day, with an intraday high of HKD 33.000, marking a new high in nearly a year [1] - On the same day, the main capital inflow was HKD 55.373 million, while outflow was HKD 94.342 million, resulting in a net outflow of HKD 38.969 million [1] Group 2 - Lepu XinTai Medical Technology (Shanghai) Co., Ltd. is a pioneer in the interventional medical device industry for structural heart disease in China and a major supplier of congenital heart disease occluders [2] - The company focuses on the research, production, and marketing of interventional devices for structural heart diseases, with 55 existing and in-development products covering a range of treatments [2] - The products have been sold to 50 countries and regions across Asia, Europe, America, and Africa, showcasing the company's strong research and development capabilities with 234 registered intellectual property rights as of April 26, 2023 [2] - The company has invested in biodegradable technology research and has received national recognition for its contributions to congenital heart disease treatment [2]
心泰医疗盘中最高价触及33.000港元，创近一年新高